Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
AssigneeGenetics Institute, Inc.
InventorsAmechand Boodhoo, Jasbir S. Seehra, Gray Shaw, Dianne Sako
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein may be administered alone, or in combination with a cytokine, lymphokine, or hematopoietic factor.
Claims38
A method of treating an inflammatory disease comprising administering to a mammal a therapeutically effective amount of a composition comprising a mature mocarhagin protein comprising an N terminal amino acid sequence chosen from:
- a) amino acids 192 to 221 of SEQ ID NO:
- 6;
- b) amino acids 192 to 221 of SEQ ID NO:
- 8;
- c) amino acids 192 to 221 of SEQ ID NO:
- 10;
- d) amino acids 192 to 221 of SEQ ID NO:
- 12;
- e) amino acids 192 to 221 of SEQ ID NO:
- 14.
A method of treating an inflammatory disease comprising administering to a mammal a therapeutically effective amount of a composition comprising a mocarhagin protein comprising an amino acid sequence chosen from:
- a) SEQ ID NO:
- 6;
- b) SEQ ID NO:
- 8;
- c) SEQ ID NO:
- 10;
- d) SEQ ID NO:
- 12;
- e) SEQ ID NO:
- 14.
A method of treating an inflammatory disease comprising administering to a mammal a therapeutically effective amount of a composition comprising a fragment of a mocarhagin protein, wherein the fragment of the mocarhagin protein has mocarhagin activity, and comprises a portion of any amino acid sequence chosen from:
- a) SEQ ID NO:
- 6;
- b) SEQ ID NO:
- 8;
- c) SEQ ID NO:
- 10;
- d) SEQ ID NO:
- 12;
- and
- e) SEQ ID NO:
- 14.
A method of inhibiting selectin-mediated binding comprising administering to a mammal a therapeutically effective amount of a composition comprising a mature mocarhagin protein comprising an N terminal amino acid sequence chosen from:
- a) amino acids 192 to 221 of SEQ ID NO:
- 6;
- b) amino acids 192 to 221 of SEQ ID NO:
- 8;
- c) amino acids 192 to 221 of SEQ ID NO:
- 10;
- d) amino acids 192 to 221 of SEQ ID NO:
- 12;
- e) amino acids 192 to 221 of SEQ ID NO:
- 14.
A method of inhibiting selectin-mediated binding comprising administering to a mammal a therapeutically effective amount of a composition comprising mocarhagin protein comprising an amino acid sequence chosen from:
- a) SEQ ID NO:
- 6;
- b) SEQ ID NO:
- 8;
- c) SEQ ID NO:
- 10;
- d) SEQ ID NO:
- 12;
- e) SEQ ID NO:
- 14.
A method of inhibiting selectin-mediated binding comprising administering to a mammal a therapeutically effective amount of a composition comprising a fragment of a mocarhagin protein, wherein the fragment of the mocarhagin protein has mocarhagin activity, and comprises a portion of any amino acid sequence chosen from:
- a) SEQ ID NO:
- 6;
- b) SEQ ID NO:
- 8;
- c) SEQ ID NO:
- 10;
- d) SEQ ID NO:
- 12;
- and
- e) SEQ ID NO:
- 14.
Dependencies are inferred from the claim text.